|
|
|
08 Mar 2006 |
CoTherix Initiates Trial of Ventavis in Combination With Sildenafil for Pulmonary Arterial Hypertension
|
|
08 Mar 2006 |
Santarus Announces Positive Results with ZEGERID in Nocturnal Acid Breakthrough Clinical Study; Clinical Study Evaluated ZEGERID and Major PPI Brands Nexium and Prevacid
|
|
08 Mar 2006 |
BiPar Sciences Announces Start of Phase 1 Clinical Trial for BSI-201 in Patients With Advanced Cancer
|
|
07 Mar 2006 |
Results of phase-III clinical studies of an anti-Parkinson's disease drug Istradefylline/KW-6002 conducted overseas
|
|
07 Mar 2006 |
IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
|
|
07 Mar 2006 |
IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
|
|
07 Mar 2006 |
Titan Initiates Controlled Phase II Clinical Study of DITPA in the Treatment of Elevated Cholesterol Levels
|
|
07 Mar 2006 |
Quigley Submits Investigational New Drug Application to the FDA for Its QR-333 Diabetic Peripheral Neuropathy Compound; Filing Allows Quigley to Begin Human Clinical Trials Following a 30-Day Review Period
|
|
07 Mar 2006 |
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
|
|
07 Mar 2006 |
ALTANA submitted New Drug Applications For Ciclesonide Nasal Spray in the
|
|
07 Mar 2006 |
Critical Therapeutics Announces Research on ZYFLO(R) Presented at 2006 AAAAI Annual Meeting
|
|
07 Mar 2006 |
Cubist Pharmaceuticals Reports Positive Outcome from FDA Anti-Infective Drugs Advisory Committee; PDUFA Date for FDA Review of CUBICIN sNDA is March 24th
|
|
07 Mar 2006 |
Indevus Provides Update on Two Clinical Programs; Company Completes Enrollment in Phase II Trial for Pagoclone and First Phase III Trial for SANCTURA XR(TM)
|
|
07 Mar 2006 |
Clinical Data Evaluating CC-10004 as New Oral Therapy in Severe Psoriasis
|
|
06 Mar 2006 |
Tibotec Announces FDA Acceptance for Review of NDA for TMC114
|
|
06 Mar 2006 |
Point Therapeutics' Diabetes Program Presented at Keystone Symposium; PT-630 Demonstrates Improvement of Glucose Regulation and Metabolic Parameters Associated With Progression of Type 2 Diabetes
|
|
06 Mar 2006 |
Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
|
|
06 Mar 2006 |
Icagen Provides Update on Status of Enrollment in Pivotal Phase III Trial of ICA-17043
|
|
06 Mar 2006 |
Cortex Reports Positive Results with CX717 on the Primary Outcome Measure in Adult ADHD Study; Conference Call Scheduled for 10:00 AM EST on March 8, 2006
|
|
04 Mar 2006 |
Schering-Plough Provides Update on Phase II Study of Vicriviroc
|
|
04 Mar 2006 |
Acorda Therapeutics(R) Announces Completion of Enrollment in Fampridine-SR Clinical Trial in Multiple Sclerosis and Expansion of Sales Force for Zanaflex Capsules(TM)
|
|
04 Mar 2006 |
Results of Large Phase IV Study Show Differin (adapalene gel) Gel, 0.1% Works Well in Combination With Systemic or Other Topical Agents
|
|
04 Mar 2006 |
Anacor Announces Positive Phase 1 and Preclinical Data for Novel Topical Atopic Dermatitis Agent
|
|
04 Mar 2006 |
Anacor's Novel Topical Antifungal Agent for Onychomycosis Demonstrates Good Safety Profile and Diverse Activity in Multiple Preclinical Studies
|
|
04 Mar 2006 |
Low-Dose Regimens of Soriatane (Acitretin) Effective in the Treatment of Moderate-to-Severe Plaque-Type Psoriasis; New Data Presented at AAD Shows Lower Doses of Soriatane Are Effective as Maintenance Therapy and Well-Tolerated
|
|
03 Mar 2006 |
Advanced Magnetics Announces Design of Phase III Iron Therapy Program for Ferumoxytol
|
|
03 Mar 2006 |
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma
|
|
03 Mar 2006 |
Novartis seeks EU approval for Exforge®, a powerful combination of two leading blood pressure medicines in a convenient once-daily tablet
|
|
03 Mar 2006 |
Inflazyme and Helicon Initiate the Phase IIa Clinical Trial with IPL455,903 in Age Associated Memory Impairment
|
|
03 Mar 2006 |
Medicis Announces FDA Approval of Broader Indication for VANOS
|
|
02 Mar 2006 |
Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
|
|
02 Mar 2006 |
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia
|
|
02 Mar 2006 |
NicOx compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration
|
|
02 Mar 2006 |
Alcon Laboratories withdraws its application for RETAANE
|
|
02 Mar 2006 |
Basilea (SWX: BSLN) announces positive phase III results for ceftobiprole, its first-in-class anti-MRSA cephalosporin
|
|
02 Mar 2006 |
Genaera Announces Interim Evizon™ Phase Ii (Msi-1256f-209) Data
|
|
01 Mar 2006 |
ArQule Discovers Second Activated Checkpoint Therapy(SM) Compound; Company Moves Forward With Preclinical Development of ARQ 171, Second Product Under Roche Partnership
|
|
28 Feb 2006 |
Scientific Advice From European Regulatory Authorities Confirms Progression-Free Survival Data Acceptable for Satraplatin Submission
|
|
28 Feb 2006 |
CollaGenex Pharmaceuticals' Announces Filing of Marketing Authorization Application for ORACEA(TM) with the Medicines & Healthcare Products Regulatory Agency in the United Kingdom
|
|
28 Feb 2006 |
TorreyPines Therapeutics Initiates Second Phase 1 Study for NGX267, A Selective M1 Agonist for Treatment of Alzheimer’s Disease
|
|
28 Feb 2006 |
Santarus Receives FDA Approval for ZEGERID Capsules; First and Only Immediate-Release Proton Pump Inhibitor in Convenient Capsule Form
|
|
27 Feb 2006 |
Cipralex® - new data supports the superiority of Cipralex® compared to Paxil®/Seroxat®
|
|
27 Feb 2006 |
MediciNova Announces Completion of Enrollment in a Phase II/III Generalized Anxiety Disorder Trial With MN-305
|
|
27 Feb 2006 |
GPC Biotech Presents New Satraplatin Clinical Data from Pharmacokinetics Study at ASCO Prostate Cancer Symposium
|
|
25 Feb 2006 |
Novartis receives ''approvable letter'' from the FDA for zoledronic acid 5 mg in the treatment of Paget's disease of the bone
|
|
25 Feb 2006 |
Alcon Receives Positive Opinion for DuoTrav(TM) Eye Drops Solution from CHMP
|
|
24 Feb 2006 |
Boehringer Ingelheim receives recommendation from EU scientific committee for Sifrol®/ Mirapexin®(pramipexole) for the treatment of Restless Legs Syndrome (RLS)
|
|
24 Feb 2006 |
Glenmark’s anti-diabetic, DPP-IV inhibitor, GRC 8200 successfully completes Phase I
|
|
24 Feb 2006 |
ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma
|
|
24 Feb 2006 |
Access Pharmaceuticals Announces the Commencement of a New AP5346 Clinical Study
|
| |
|
Results 5001 - 5050 of 5255 |
